TRIANA Biomedicines appoints Mohan Bala as chief operating officer

TRIANA Biomedicines, Inc., a biopharmaceutical company focused on molecular glue discovery platforms, announced the appointment of Mohan Bala as Chief Operating Officer. The company also added Maria Koehler and David Tuveson to its Scientific Advisory Board.

Bala brings over 30 years of industry experience in program leadership, development, market access, and business development. He previously served as Chief Development Officer at Mersana Therapeutics and Chief Operating Officer at Constellation Pharmaceuticals. Throughout his career, he contributed to the launch of seven oncology products globally. Bala holds a PhD in Management Science from the University of Chicago.

Maria Koehler, a board-certified hematologist-oncologist, currently serves as a Partner at Omega Funds and senior advisor to Viking Global Investors LP. She has over 20 years of oncology drug development experience and previously held leadership positions at Repare Therapeutics, Bicycle Therapeutics, and Pfizer Oncology. Koehler earned her MD and PhD from Silesian School of Medicine in Poland.

David Tuveson serves as Director of the Cold Spring Harbor Laboratory Cancer Center and Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory. He is Chief Scientist of the Lustgarten Foundation for Pancreatic Cancer Research and past President of the American Association for Cancer Research. Tuveson has been elected to the National Academy of Medicine and the American Academy of Arts and Sciences.

The appointments support the advancement of TRIANA's molecular glue degrader pipeline, including TRI-611 for ALK+ non-small cell lung cancer. The company is headquartered in Lexington, Massachusetts, and focuses on targeting disease proteins that are difficult to address with other therapeutic modalities.

You May Also Be Interested In

• Honeywell shuffles leadership in process and building units
• First Pacific Bank names new CFO as longtime executive retires
• Telescope Innovations names Dr. Neil Lewis to its board